Key result
Intranasal etripamil receives first US approval to convert acute symptomatic PSVT to sinus rhythm.
Why the study?
This article summarizes the milestones in the development of etripamil leading to its first approval for the treatment of symptomatic paroxysmal supraventricular tachycardia.
Answers are grounded in this paper and cite their sources.
Etripamil is the first approved intranasal L-type calcium channel blocker for the acute conversion of symptomatic PSVT to sinus rhythm in adults.
) is an intranasal L-type calcium channel blocker (CCB) developed by Milestone Pharmaceuticals for the treatment of symptomatic paroxysmal supraventricular tachycardia (PSVT) and is under investigation for atrial fibrillation with rapid ventricular rate (AF-RVR). It received its first approval on the 12 December 2025 in the USA for the conversion of acute symptomatic PSVT episodes to sinus rhythm in adults. Additional global regulatory filings of etripamil for PSVT in adults, a phase II trial of etripamil in pediatrics, and a phase III trial for AF-RVR are in progress. This article summarizes the milestones in the development of etripamil leading to this first approval for PSVT.
No takes yet. Share an insight, caveat, or question.
Michael B. Brown (2026) conducted a review in Symptomatic paroxysmal supraventricular tachycardia (PSVT). Etripamil was evaluated on Conversion of acute, symptomatic PSVT episodes to sinus rhythm. Etripamil, an intranasal L-type calcium channel blocker, received its first approval in the USA for the conversion of acute, symptomatic PSVT episodes to sinus rhythm in adults.
Synapse has enriched 10 related papers. Consider them for comparative context: